Maturation and Development. Biological and Psychological Perspectives

Total Page:16

File Type:pdf, Size:1020Kb

Maturation and Development. Biological and Psychological Perspectives J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.46.4.375-b on 1 April 1983. Downloaded from Journal of Neurology, Neurosurgery, and Psychiatry 1983;46:375-376 definition by trained transcribers with an tumours in childhood. Book reviews interexaminer reliability of F = 0-81 fol- These volumes are much recommended Gilies de la Tourette Syndrome Volume 35 lowed by 2-way Anovas with blocking for to all neurosurgeons who wish to be of Advances in Neurology. Edited by subject pairs to compute F ratios for com- acquainted with the "state of play" in Arnold J Friedhoff and Thomas N Chase. paring the mean Z scores on each language paediatric neurosurgery. The editors are, (Pp 478; $58.90.) New York, Raven Press. function. This is incomprehensible as well however, very naive if they believe, as they 1982. as meaningless. It is impossible to find out suggest in their preface to volume 2, that it whether clonidine is really useful or not or may be "possible for paediatric This volume contains the proceedings of whether haloperidol does possess definite neurosurgeons throughout the entire world the 1981 New York symposium on advantages over other neuroleptics. to provide their knowledge and care to the Tourette syndrome. The 67 papers are This is the second major work on Gilles benefit of all children". At least 1000 mil- organised into 10 main sections, clinical de la Tourette's syndrome to appear in 4 lion of the world's population are provided and historical over-view, neuro-anatomy years, the first edited by the Shapiros, with very few neurosurgeons (for the and neuropathology, neurophysiology, Bruun, and Sweet. Although de la Tourette treatment of adults and children)-about biochemistry, animal models, genetics, recognised that the illness was a movement 1% of the proportion serving the USA. epidemiology and population studies, disorder, not a form of madness or insanity, Paediatric neurosurgery must have a very psychology and psychiatry, neurology and the wealth of neuroscience in this book low priority in those areas. speech pathology, and clinical pharmacol- contributes little to understanding the syn- KENNETH TILL ogy. Despite a total of 444 pages plus index drome. To be more than a record the pub- written by a total of 148 contributors, the lication of conference proceedings needs nature and origin of Gilles de la Tourette's more careful selection, more detailed Maturation and Development. Biological syndrome remain unknown, the pathology editorship and more critical comment than and Psychological Perspectives. Edited by is virtually non-existent and any relevant appear here. Kevin J Connolly and Heinz FR Prechtl. neurochemistry at best fragmentary. Selec- JD PARKES (Pp 326; £15-00.) London: Spastics tive reading is therefore required. The best International Medical Publications, 1981. section in the book is the introduction with the re-appearance of Murray's delightful Concepts in Pediatric Neurosurgery, Vols The concepts of development of the Protected by copyright. essay on Samuel Johnson's movement dis- 1 and 2. The American Society for Pediatric maturation, although seemingly straight- order and also the first English translation Neurosurgery. (Pp 222; SFr 190, DM 228, forward, have proved problematic in of Gilles de la Tourette on Tourette's syn- $114.00 each.) Basel: S Karger AG, 1982. practice. As Dr Ronnie Mac Keith, to drome. The next section, that on neuro- whom this set of essays is dedicated, often anatomy and neuropathology reviews dif- These two volumes are the first of a con- pointed out, the terms tend to be used ferent aspects of monoamine and peptide tinuing series to provide a forum for those interchangeably as both empirical des- systems in the brain but contains little of who can contribute to the burgeoning spe- criptors and as explanatory theoretical direct relevance to the book's title, apart ciality of paediatric neurosurgery. constructs-a dangerous mixture as the from Richardson's review of two negative Although, no doubt, many of the chapters outmoded concepts of instinct and drive necropsies on ticquers. Peptides, cerebro- are derived from recently published pap- showed. Moreover, as explanations the spinal fluid amine metabolites, and the sub- ers, they provide under the heading of terms tend to assume more knowledge on stantia nigra all appear in the 80 pages on "Concepts" more considered accounts of brain-behaviour relationships than actually biochemistry, again usually without direct past experience and a more sober review of exists. I rather doubt that Ronnie would relevance to Tourette' s syndrome. The present progress than one obtains in the have been satisfied by the answers provided animal models of neuropsychiatric disorder usual proceedings or symposiums which in this book although, certainly, he would in rats, mice, rabbits, hampsters, guinea- often masquerade as a new book. have been pleased that the topic has been pigs and the like, show enormous ingenuity In such a rapidly developing field, it is given a critical scrutiny. The volume is too but rarely mimic Dr Samuel Johnson's ges- extremely important for those fortunate lacking in integration to be wholly satisfying http://jnnp.bmj.com/ ticulations, tics, or compulsive behaviour. enough to be acquiring extensive experi- but it contains much of interest and value. The genetic and epidemiological data are ence to communicate this to others. Thus in Thus, Polani gives an authoritative and of major interest with detailed information these volumes there are chapters on par- readable account of chromosomal mech- on the very high frequency of ticquers in ticular tumours (craniopharyngioma, anisms and developmental anomalies, van different populations. Perhaps it is surpris- medulloblastoma etc.) on the value of par- Hof succinctly discusses developmental ing that haloperidol rather than vital ticular investigative procedures (met- issues relevant to the neural mechanisms energy is used to treat Chinese patients, rizimide CIT cistemography, telimetric underlying recovery from brain damage, but not surprising that HLA typing in pressure measurements) on particular and Judy Dunn provides a brief but American patients is no different from that treatment methods (cutaneous third ven- thoughtful discussion of maturation in on September 29, 2021 by guest. in American non-ticquers. In contrast to triculostomy etc) while other chapters pro- relation to early social development-to this brief section those on psychology, vide reviews of broader subjects such as a give three rather different examples. The psychiatry, language and clinical phar- comparison of different methods of tumour main weakness in the book concerns the macology are a little disappointing. The use treatment, neurosurgical management of psychological implications of the biological of jargon and over-classification can be myelomeningocele, management of uri- findings. Thus, little is said on brain- misleading as when analytical procedures nary incontinence; a chapter worthy of behaviour relationships, or on the effects of are used to classify vocal tics into eleven special mention is a summary of reaching puberty early or late or on some of different categories according to specific papovaviruses and the causation of brain the conditions (such as enuresis) in which 375 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.46.4.375-b on 1 April 1983. Downloaded from 376 Book reviews concepts of "maturational delay" are most advance in terms of selectivity and fre- decessors. The anatomy is comprehensive often invoked. Ronnie would have been quency of unwanted effects. What has also and provides satisfying detail for both the especially disappointed by the last of these interested psychopharmacologists is the neuroanatomy student and the clinician. omissions but perhaps it was not discussed great variation in pharmacological effects Although it remains a predominantly because the queries he raised have yet to be between the new antidepressants. As yet anatomical text, it includes adequate answered and because there is little new to there is no satisfactory correlation between descriptions of related physiology, and report. The book deserves to be widely read their clinical effects and pharmacological where relevant, clinical topics are as much for the implicit unanswered actions but if it can be demonstrated that explained in brief vignettes. Some of these questions that arise, as for the wealth of they are effective antidepressants it shows are masterpieces of succinct, accurate and factual information it provides. that the old catecholamine hypothesis of illuminating writing. MICHAEL RUTTER affective disorders is untenable. In this vol- The clinical applications of anatomy and ume there is undeniable evidence that sev- physiology are explained for example in eral of the newer drugs are highly effective tests of vestibular function, visual fixation Low Back Pain-Assessment and Man- antidepressants, including bupropion, and muscle stretch reflexes. The correla- agement. By Dan M Spengler. (Pp 160; zimelidine, trazodone and mianserin. It is tions of syndromes with disturbed anatomy $24.00; £16-00.) New York: Grune and also clear that several other drugs have and physiology are shown in spinal cord Stratton Inc. 1982. interesting pharmacological effects consis- lesions, and in the brain stem infarcts which tent with their use of antidepressants but spawn so many eponyms. These are all There are too many books on backache their clinical efficacy is still not proven described with commendable clarity and which simply re-write standard teaching fully. These drugs include clovoxamine, brevity. A highlight of the book is a mul- and it is a pleasure to find an exception. sulpiride, viloxazine and amoxapine. The titude of superb, simple, line diagrams and Most books start with anatomy and disease book is a companion text to volume 31 of figures, each carefully conceived and label- and proceed to medical technology. Speng- the series; this is concerned primarily with led. ler starts with the patient and his pain and the mechanisms of action of antide- Any subject with such wide ramifications proceeds to clinical decision making and pressants.
Recommended publications
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • European Journal of Pharmacology 753 (2015) 2–18
    European Journal of Pharmacology 753 (2015) 2–18 Contents lists available at ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Review Serotonin: A never-ending story Berend Olivier a,b,n a Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences & Brain Center Rudolf Magnus, Utrecht University, Universiteitsweg 99, 3584CG Utrecht, The Netherlands b Department of Psychiatry, Yale University School of Medicine, New Haven, USA article info abstract Article history: The neurotransmitter serotonin is an evolutionary ancient molecule that has remarkable modulatory Accepted 16 October 2014 effects in almost all central nervous system integrative functions, such as mood, anxiety, stress, aggression, Available online 7 November 2014 feeding, cognition and sexual behavior. After giving a short outline of the serotonergic system (anatomy, Keywords: receptors, transporter) the author's contributions over the last 40 years in the role of serotonin in Serotonin depression, aggression, anxiety, stress and sexual behavior is outlined. Each area delineates the work Depression performed on animal model development, drug discovery and development. Most of the research work Anxiety described has started from an industrial perspective, aimed at developing animals models for psychiatric Aggression diseases and leading to putative new innovative psychotropic drugs, like in the cases of the SSRI SSRI fluvoxamine, the serenic eltoprazine and the anxiolytic flesinoxan. Later this research work mainly focused Fluvoxamine on developing translational animal models for psychiatric diseases and implicating them in the search for mechanisms involved in normal and diseased brains and finding new concepts for appropriate drugs. & 2014 Elsevier B.V. All rights reserved. Contents 1. Serotonin, history, drugs .
    [Show full text]
  • Tcas Versus Placebo - New Studies in the Guideline Update
    TCAs versus placebo - new studies in the guideline update Comparisons Included in this Clinical Question Amitriptyline vs placebo Clomipramine vs placebo Dosulepin (dothiepin) vs placebo AMSTERDAM2003A LARSEN1989 FERGUSON1994B BAKISH1992B PECKNOLD1976B ITIL1993 BAKISH1992C RAMPELLO1991 MINDHAM1991 BREMNER1995 THOMPSON2001B CLAGHORN1983 CLAGHORN1983B FEIGHNER1979 GELENBERG1990 GEORGOTAS1982A GOLDBERG1980 HICKS1988 HOLLYMAN1988 HORMAZABAL1985 HOSCHL1989 KLIESER1988 LAAKMAN1995 LAPIERRE1991 LYDIARD1997 MYNORSWALLIS1995 MYNORSWALLIS1997 REIMHERR1990 RICKELS1982D RICKELS1985 RICKELS1991 ROFFMAN1982 ROWAN1982 SMITH1990 SPRING1992 STASSEN1993 WILCOX1994 16 Imipramine vs placebo BARGESCHAAPVELD2002 BEASLEY1991B BOYER1996A BYERLEY1988 CASSANO1986 CASSANO1996 CLAGHORN1996A COHN1984 COHN1985 COHN1990A COHN1992 COHN1996 DOMINGUEZ1981 DOMINGUEZ1985 DUNBAR1991 ELKIN1989 ENTSUAH1994 ESCOBAR1980 FABRE1980 FABRE1992 FABRE1996 FEIGER1996A FEIGHNER1980 FEIGHNER1982 FEIGHNER1983A FEIGHNER1983B FEIGHNER1989 FEIGHNER1989A FEIGHNER1989B FEIGHNER1989C FEIGHNER1992B FEIGHNER1993 FONTAINE1994 GELENBERG2002 GERNER1980B HAYES1983 ITIL1983A KASPER1995B KELLAMS1979 LAIRD1993 LAPIERRE1987 LECRUBIER1997B LIPMAN1986 LYDIARD1989 MARCH1990 17 MARKOWITZ1985 MENDELS1986 MERIDETH1983 Nortriptyline vs placebo NANDI1976 GEORGOTAS1986A NORTON1984 KATZ1990 PEDERSEN2002 NAIR1995 PESELOW1989 WHITE1984A PESELOW1989B PHILIPP1999 QUITKIN1989 RICKELS1981 RICKELS1982A RICKELS1987 SCHWEIZER1994 SCHWEIZER1998 SHRIVASTAVA1992 SILVERSTONE1994 SMALL1981 UCHA1990 VERSIANI1989 VERSIANI1990
    [Show full text]
  • Antidepressant Prophylaxis Reduces Depression Risk but Does Not
    REVIEW Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C patients receiving interferon without depression at baseline: A systematic review and meta-analysis Awad Al-Omari MD1, Juthaporn Cowan MD1, Lucy Turner BSc MSc2, Curtis Cooper MD FRCPC1,2 A Al-Omari, J Cowan, L Turner, C Cooper. Antidepressant Les antidépresseurs en prophylaxie réduisent le risque de prophylaxis reduces depression risk but does not improve dépression mais n’améliorent pas la réponse virologique sustained virological response in hepatitis C patients receiving soutenue chez les patients atteints d’hépatite C qui interferon without depression at baseline: A systematic review reçoivent de l’interféron sans être déprimés au départ : and meta-analysis. Can J Gastroenterol 2013;27(10):575-581. une analyse systématique et une méta-analyse BACKGROUND: Depression complicates interferon-based hepatitis C HISTORIQUE : La dépression complique l’antivirothérapie à l’interféron virus (HCV) antiviral therapy in 10% to 40% of cases, and diminishes conte le virus de l’hépatite C (VHC) chez 10 % à 40 % des patients et patient well-being and ability to complete a full course of therapy. As réduit leur bien-être et leur capacité de terminer le traitement. Par con- a consequence, the likelihood of achieving a sustained virological séquent, la probabilité d’obtenir une réponse virologique soutenue (RVS response (SVR [ie, permanent viral eradication]) is reduced. [c.-à-d. une éradication virale permanente]) est réduite. OBJECTIVE: To systematically review the evidence of whether pre- OBJECTIF : Procéder à l’analyse systématique des données probantes emptive antidepressant prophylaxis started before HCV antiviral pour déterminer si une prophylaxie préventive aux antidépresseurs amor- initiation is beneficial.
    [Show full text]
  • Typical and Atypical Antidepressants. Clinical Practice
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.46.4.376-a on 1 April 1983. Downloaded from 376 Book reviews concepts of "maturational delay" are most advance in terms of selectivity and fre- decessors. The anatomy is comprehensive often invoked. Ronnie would have been quency of unwanted effects. What has also and provides satisfying detail for both the especially disappointed by the last of these interested psychopharmacologists is the neuroanatomy student and the clinician. omissions but perhaps it was not discussed great variation in pharmacological effects Although it remains a predominantly because the queries he raised have yet to be between the new antidepressants. As yet anatomical text, it includes adequate answered and because there is little new to there is no satisfactory correlation between descriptions of related physiology, and report. The book deserves to be widely read their clinical effects and pharmacological where relevant, clinical topics are as much for the implicit unanswered actions but if it can be demonstrated that explained in brief vignettes. Some of these questions that arise, as for the wealth of they are effective antidepressants it shows are masterpieces of succinct, accurate and factual information it provides. that the old catecholamine hypothesis of illuminating writing. MICHAEL RUTTER affective disorders is untenable. In this vol- The clinical applications of anatomy and ume there is undeniable evidence that sev- physiology are explained for example in eral of the newer drugs are highly effective tests of vestibular function, visual fixation Low Back Pain-Assessment and Man- antidepressants, including bupropion, and muscle stretch reflexes. The correla- agement.
    [Show full text]
  • Dawson, S., Maund, E., Stuart, B., Moore, M., Christopher, D
    Dawson, S. , Maund, E., Stuart, B., Moore, M., Christopher, D., Geraghty, A. WA., & Kendrick, T. (2019). Managing Antidepressant Discontinuation: A Systematic Review. Annals of Family Medicine, 17(1), 52-60. https://doi.org/10.1370/afm.2336 Peer reviewed version License (if available): Other Link to published version (if available): 10.1370/afm.2336 Link to publication record in Explore Bristol Research PDF-document This is the accepted author manuscript (AAM). The final published version (version of record) is available online via the Annals of Family Medicine at https://doi.org/10.1370/afm.2336 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Supplemental materials for: Maund E, Stuart B, Moore M, et al. Managing antidepressant discontinuation: a systematic review. Ann Fam Med. 2019;17(1):52-60. 1 Supplemental APPENDIX 1 - SEARCH STRATEGIES MEDLINE Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 23 March 2017 Search Query Items ID# found 1 exp ANTIDEPRESSIVE AGENTS/ 133782 2 exp NEUROTRANSMITTER UPTAKE INHIBITORS/ 133192 3 (psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 136112 noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*).ti,kf,hw.
    [Show full text]
  • PRODUCT MONOGRAPH NOVO–FLUVOXAMINE (Fluvoxamine Maleate) Tablets Antidepressant/Antiobsessional Agent Teva Canada Limited
    PRODUCT MONOGRAPH NOVO–FLUVOXAMINE (Fluvoxamine Maleate) Tablets Antidepressant/Antiobsessional Agent Teva Canada Limited Date of Preparation: Toronto, Canada June 6, 2014 Control # 174215 PRODUCT MONOGRAPH NOVO-FLUVOXAMINE (Fluvoxamine Maleate) Tablets THERAPEUTIC CLASSIFICATION Antidepressant/Antiobsessional Agent ACTION AND CLINICAL PHARMACOLOGY The antidepressant and antiobsessional actions of fluvoxamine are believed to be related to its selective inhibition of presynaptic serotonin re-uptake in brain neurons. There is minimum interference with noradrenergic processes and, in common with several other specific inhibitors of serotonin uptake, fluvoxamine has very little in vitro affinity for α1, α2, β1, dopamine2, histamine1, serotonin1,serotonin2 or muscarinic receptors. Pharmacokinetics In healthy volunteers, fluvoxamine is well absorbed after oral administration. Following a single 100 mg oral dose, peak plasma levels of 31-87 ng/mL were attained 1.5 to 8 hours post-dose. Peak plasma levels and AUC's (0-72 hours) are directly proportionate to dose after single oral doses of 25, 50, and 100 mg. Following single doses, the mean plasma half-life is 15 hours, and slightly longer (17-22 hours), during repeated dosing. Steady-state plasma levels are usually achieved within 10-14 days. The pharmacokinetic profile in the elderly is similar to that in younger patients. Metabolism and Elimination Fluvoxamine undergoes extensive hepatic transformation, mainly via oxidative demethylation, to at least nine metabolites, which are excreted by the kidney. Ninety-four percent of an oral radioactive dose is recovered in the urine within 48 hours. The two major metabolites showed negligible pharmacological activity. In vitro binding of fluvoxamine to human plasma proteins is about 77% at drug concentrations up to 4000 ng/mL.
    [Show full text]
  • Drugs/Medications Known to Cause Hyperhidrosis Certain Prescriptions
    Drugs/Medications Known to Cause Hyperhidrosis Certain prescriptions and non-prescription medications can cause hyperhidrosis (excess perspiration or sweating) as a side effect. A list of potentially sweat-inducing medications is provided below. Medications are listed alphabetically by generic name. U.S. brand names are given in parentheses, if applicable. This list is provided as a resource and a service. It is not exhaustive and is in no way meant to replace consultation with a medical professional. Although sweating is a known side effect of the medications listed below, in most cases only a small percentage of people using the medicines experience undue sweating (in some cases less than 1%). Medications noted with an “*” and in bold are the most likely to cause sweating and the frequency of sweating as a side effect from these medications may be as high as 50%. Medications noted with an “†” are commonly-prescribed drugs; and those with a “P” are often used for pediatrics. Key: */Bold -- Known to commonly cause hyperhidrosis † -- Commonly-prescribed drugs P -- Pediatric use Abciximab (ReoPro®) Acamprosate (Campral®) Acetaminophen and Tramadol (Ultracet™) Acetophenazine (NA) Acetylcholine (Miochol-E®) P Acetylcysteine (Acetadote®) P Acitretin (Soriatane®) Acrivastine and Pseudoephedrine (Semprex®-D) † Acyclovir (Zovirax®) P Adenosine (Adenocard®; Adenoscan®) † Albuterol (Proventil® HFA Inhalation Aerosol) Alemtuzumab (Campath®) Alizapride (NA) Almotriptan (Axert™) Alosetron (Lotronex®) Amonafide (NA) Ambenonium (Mytelase®) Amitriptyline
    [Show full text]
  • Antidepressant Treatment for Postnatal Depression
    This is a repository copy of Antidepressant treatment for postnatal depression. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/163986/ Version: Published Version Article: Brown, Jennifer Valeska Elli orcid.org/0000-0003-0943-5177, Wilson, Claire A., Ayre, Karyn et al. (5 more authors) (2020) Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews. CD013560. ISSN 1469-493X https://doi.org/10.1002/14651858.CD013560 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Library Cochrane Database of Systematic Reviews Antidepressant treatment for postnatal depression (Protocol) Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H. Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD013560. DOI: 10.1002/14651858.CD013560. www.cochranelibrary.com Antidepressant treatment for postnatal depression (Protocol) Copyright © 2020 The Cochrane Collaboration.
    [Show full text]
  • Letters to the Editor
    Letters to the Editor Letters to the Editor ©Mirtazapine-Associated Copyright 2001 Palinopsia Physicianswithdrawal Postgraduate of mirtazapine suggests Press, that mirtazapineInc. might have been the trigger for the phenomenon. Trazodone, nefazo- Sir: Mirtazapine is a combined noradrenergic and selective done, risperidone, and mirtazapine share antagonism at the serotonergic antagonist that is effective in the treatment of de- 5-HT2 receptor. LSD is a 5-HT2A and 5-HT2C agonist, and post- pression. The most common side effects of mirtazapine include hallucinogen perception disorder might be related to reduced dry mouth, drowsiness, sedation, increased appetite, and weight receptor stimulation. Our patient’s visual disturbance lends sup- gain.1 We report an unusual visual disturbance in one of our pa- port to the hypothesis that palinopsia is associated with 5-HT2 tients. antagonism or reduced 5-HT2 receptor stimulation. REFERENCES Case report. Ms. A, a 26-year-old woman with obsessive- compulsive personality disorder, sought treatment for her first 1. Montgomery SA. Safety of mirtazapine: a review. Int Clin major depressive episode, which was moderate and without psy- Psychopharmacol 1995;10(suppl 4):37–45 chotic features (DSM-IV). She had developed significant de- 2. Pomeranz HD, Lessell S. Palinopsia and polyopia in the absence pressed and irritable mood, restlessness,One increased personal anxiety, copy may beof drugs printed or cerebral disease. Neurology 2000;54:855–859 decreased appetite, and initial insomnia. She had a positive fam- 3. Kawasaki A, Purvin VA. Persistent palinopsia following ingestion of ily history for depression and felt that the depressive symptoms lysergic acid diethylamide (LSD). Arch Ophtalmol 1996;114:47–50 had an association with a significant life transition.
    [Show full text]
  • (73) Assignee: Epicept Corporation, Englewood E. E. E. N. "...O's E Cliffs, NJ (US) 6,245,781 B1 6/2001 Upadhyay Et Al
    USOO6638981B2 (12) UnitedO States Patent (10) Patent No.: US 6,638,981 B2 Williams et al. (45) Date of Patent: Oct. 28, 2003 (54) TOPICAL COMPOSITIONS AND METHODS 6,191,131 B1 2/2001. He et al. .................... 514/246 FOR TREATING PAIN 6,191,165 B1 2/2001 Ognyanov et al. .......... 514/523 6,197.830 B1 3/2001 Frome ........................ 514/654 (75) Inventors: Robert O. Williams, Austin, TX (US); 3.24-Y-2 R : E.aS C al.al ...........- - - - - - sy: Feng Zhang, Austin, TX (US) 6,225,324 B1 5/2001 Poss et al. .................. 514/316 (73) Assignee: Epicept Corporation, Englewood E. E. E. N. "...O's E Cliffs, NJ (US) 6,245,781 B1 6/2001 Upadhyay et al. .......... 514/321 - 6,251,903 B1 6/2001 Cai et al. .................... 514/249 (*) Notice: Subject to any disclaimer, the term of this 6.251948 B1 6/2001 Weber et al. ............... 514/634 patent is extended or adjusted under 35 6.255,302 B1 7/2001 Kelly et al. ............ 514/217.05 U.S.C. 154(b) by 0 days. 6,387,957 B1 5/2002 Frome ........................ 514/647 6,461,600 B1 10/2002 Ford ....................... 424/78.02 (21) Appl. No.: 09/931,293 FOREIGN PATENT DOCUMENTS (22) Filed: Aug. 17, 2001 EP O 107 376 A1 5/1984 (65) Prior Publication Data EP O 577 394 A1 1/1994 WO WO 93/10163 5/1993 US 2003/0082214 A1 May 1, 2003 WO WO 94/13643 6/1994 (51) Int. Cl. .............................................. A61K31/135 W. WO 94/13644 6/1994 WO WO 94/13661 6/1994 (52) U.S.
    [Show full text]